How Will Recce’s New China Patent Transform Its Anti-Infective Ambitions?
Recce Pharmaceuticals has secured a significant patent acceptance in China for its RECCE® anti-infectives, broadening its intellectual property footprint in the world’s second-largest pharmaceutical market.
- China Intellectual Property Administration accepts new patent family for RECCE® anti-infectives
- Patent covers RECCE® 327 and RECCE® 529 for multiple bacterial and viral infections
- Includes diverse administration methods: oral, inhalation, injection, topical
- China’s antibiotic market valued at over US$4 billion with 5.7% projected growth
- Recce’s fifth patent family with parallel submissions in Australia, Canada, Israel, Japan
Recce’s Strategic Patent Milestone in China
Recce Pharmaceuticals Limited has announced a key development in its global patent strategy with the acceptance of a new patent family by the China Intellectual Property Administration. This patent family, known as Family 4, covers the company’s innovative RECCE® anti-infective compounds, specifically RECCE® 327 and RECCE® 529. The acceptance marks a critical step in securing intellectual property rights in China, the world’s second-largest pharmaceutical market.
The patent claims encompass the process for preparing these synthetic anti-infectives and their use in treating a broad spectrum of diseases, including serious bacterial and viral infections. Notably, the patent validates applications in acute bacterial skin infections, diabetic foot infections, burn wounds, lung infections such as ventilator-associated pneumonia, urinary tract infections, gonorrhoea, influenza, and even SARS-CoV-2.
Broad Spectrum and Versatile Administration
Recce’s patent protection extends beyond the compounds themselves to cover multiple administration routes. These include oral, inhalation, transdermal, and various injection methods (intramuscular and intravenous). Additionally, topical applications such as ointments, gels, foams, and aerosolized forms for mucous membranes are included. This versatility enhances the potential clinical utility and market reach of Recce’s anti-infectives.
James Graham, Recce’s CEO, highlighted the significance of this patent acceptance, emphasizing the recognition of the technical advantages of their new class of anti-infectives by Chinese authorities. The move strengthens Recce’s position in a market valued at approximately US$4.09 billion and projected to grow at a compound annual growth rate of 5.7% through 2030.
Global Patent Strategy and Market Implications
This acceptance in China complements Recce’s broader intellectual property portfolio, which includes patent families filed or granted in Australia, Canada, Israel, and Japan. The company’s synthetic anti-infectives are designed to address the urgent global health challenge of antibiotic-resistant superbugs, a growing concern recognized by the World Health Organization.
Recce’s lead compounds have garnered regulatory attention, with RECCE® 327 receiving Fast Track designation from the US FDA and inclusion on priority pathogen lists. The company’s approach leverages synthetic polymers with multiple mechanisms of action, aiming to overcome resistance issues that plague traditional antibiotics.
While the announcement does not specify timelines for commercialization or regulatory approvals within China, the patent acceptance lays a foundational step for future clinical development and market entry strategies in a critical region.
Bottom Line?
Recce’s expanding patent footprint in China signals growing momentum but leaves key commercialization questions open.
Questions in the middle?
- What are Recce’s plans and timelines for regulatory approval and market launch in China?
- How will Recce navigate competitive dynamics in China’s rapidly evolving antibiotic market?
- What clinical trial data will support the use of RECCE® compounds in Chinese patient populations?
